- Home
- RQI vs SUPN Comparison
RQI vs SUPN Comparison
Compare RQI & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RQI
- SUPN
- Stock Information
- Founded
- RQI 2002
- SUPN 2005
- Country
- RQI United States
- SUPN United States
- Employees
- RQI N/A
- SUPN N/A
- Industry
- RQI Trusts Except Educational Religious and Charitable
- SUPN Biotechnology: Pharmaceutical Preparations
- Sector
- RQI Finance
- SUPN Health Care
- Exchange
- RQI Nasdaq
- SUPN Nasdaq
- Market Cap
- RQI 1.7B
- SUPN 1.8B
- IPO Year
- RQI N/A
- SUPN 2012
- Fundamental
- Price
- RQI $12.46
- SUPN $31.70
- Analyst Decision
- RQI
- SUPN Hold
- Analyst Count
- RQI 0
- SUPN 2
- Target Price
- RQI N/A
- SUPN $36.00
- AVG Volume (30 Days)
- RQI 432.6K
- SUPN 467.8K
- Earning Date
- RQI 01-01-0001
- SUPN 05-06-2025
- Dividend Yield
- RQI 8.20%
- SUPN N/A
- EPS Growth
- RQI N/A
- SUPN N/A
- EPS
- RQI N/A
- SUPN 1.11
- Revenue
- RQI N/A
- SUPN $667,997,000.00
- Revenue This Year
- RQI N/A
- SUPN N/A
- Revenue Next Year
- RQI N/A
- SUPN $8.74
- P/E Ratio
- RQI N/A
- SUPN $28.64
- Revenue Growth
- RQI N/A
- SUPN 11.82
- 52 Week Low
- RQI $9.17
- SUPN $25.53
- 52 Week High
- RQI $12.64
- SUPN $40.28
- Technical
- Relative Strength Index (RSI)
- RQI 56.08
- SUPN 45.77
- Support Level
- RQI $11.94
- SUPN $31.56
- Resistance Level
- RQI $12.29
- SUPN $32.85
- Average True Range (ATR)
- RQI 0.20
- SUPN 0.78
- MACD
- RQI 0.00
- SUPN -0.08
- Stochastic Oscillator
- RQI 82.54
- SUPN 13.56
About RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the Fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.